The Valley Desk

NCT02104817 · Interventional trial

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Overall registry status Completed

Phase 3

Conditions Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov